Antiangiogenic therapy of cancer by multitargeted tyrosine kinase inhibitors

被引：0
|
作者：
Agata, Naoki [1 ]
机构：
[1] Pfizer Inc, Div Med, Shibuya Ku, Tokyo 1518589, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2008年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：40P / 40P
页数：1
相关论文
共 50 条
  • [21] Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials
    Yong-Ying Xiao
    Ping Zhan
    Dong-Mei Yuan
    Hong-Bing Liu
    Tang-Feng Lv
    Yong Song
    Yi Shi
    European Journal of Clinical Pharmacology, 2013, 69 : 151 - 159
  • [22] New tyrosine kinase and EGFR inhibitors in cancer therapy
    Rottlaender, D.
    Reda, S.
    Motloch, L. J.
    Hoppe, U. C.
    INTERNIST, 2011, 52 (10): : 1245 - +
  • [23] Smart drugs: Tyrosine kinase inhibitors in cancer therapy
    Shawver, LK
    Slamon, D
    Ullrich, A
    CANCER CELL, 2002, 1 (02) : 117 - 123
  • [24] Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
    Russo, Eleonora
    Spallarossa, Andrea
    Tasso, Bruno
    Villa, Carla
    Brullo, Chiara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [25] Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer
    Antonelli, Alessandro
    Fallahi, Poupak
    Ulisse, Salvatore
    Ferrari, Silvia Martina
    Mazzi, Valeria
    Di Domenicantonio, Andrea
    Miccoli, Paolo
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2015, 2 (02) : 135 - 142
  • [26] Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
    Karasic, Thomas B.
    Rosen, Mark A.
    O'Dwyer, Peter J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 661 - 671
  • [27] Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer
    Lamartina, Livia
    Ippolito, S.
    Danis, M.
    Bidault, F.
    Borget, I.
    Berdelou, A.
    Al Ghuzlan, A.
    Hartl, D.
    Blanchard, P.
    Terroir, M.
    Deandreis, D.
    Schlumberger, M.
    Baudin, E.
    Leboulleux, S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (07): : 2733 - 2741
  • [28] Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
    Thomas B. Karasic
    Mark A. Rosen
    Peter J. O’Dwyer
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 661 - 671
  • [29] Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials
    Xiao, Yong-Ying
    Zhan, Ping
    Yuan, Dong-Mei
    Liu, Hong-Bing
    Lv, Tang-Feng
    Song, Yong
    Shi, Yi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (02) : 151 - 159
  • [30] Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
    Scagliotti, Giorgio
    Govindan, Ramaswamy
    ONCOLOGIST, 2010, 15 (05): : 436 - 446
12345